Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has provided an announcement.
Imricor Medical Systems, Inc. reported significant progress in Q2 2025, with notable regulatory achievements including CE mark approvals for its Advantage-MR system and NorthStar mapping system under the new European Medical Device Regulation. The company also successfully performed the first-in-human ventricular ablation guided by real-time iCMR at Amsterdam University Medical Centre and commenced the VISABL-VT clinical trial. Financially, the company maintained a cash balance of US$50.3 million despite a temporary dip in cash receipts due to non-revenue generating clinical trial enrollments. Imricor’s European sales team expansion and ongoing regulatory advancements are expected to accelerate hospital adoption and commercial launches in Europe and the United States.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. operates in the medical technology industry, specializing in the development of MRI-compatible products for cardiac ablation procedures. The company focuses on integrating real-time MRI guidance into cardiac interventions, aiming to enhance precision and outcomes in cardiac ablation therapies.
Average Trading Volume: 392,260
Technical Sentiment Signal: Buy
See more data about IMR stock on TipRanks’ Stock Analysis page.